


I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 4, 2006 Signature: 
(Sharon M. Sintich)

Docket No.: 30847/2051-004
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Helgadottir *et al.*

Application No.: 10/769,744

Confirmation No.: 6429

Filed: January 30, 2004

Art Unit: 1646

For: Susceptibility Gene for Myocardial Infarction, Stroke,
and PAOD; Methods of Treatment Examiner: Not Yet Assigned

SEQUENCE STATEMENT PURSUANT TO 37 CFR § 1.825(A) AND(B) AND **SUBMISSION OF COMPACT DISC OF SUBSTITUTE SEQUENCE LISTING** **(37 CFR § 1.52(e))**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Submitted herewith in lieu of a paper copy of the substitute Sequence Listing, and in accordance with 37 CFR 1.52(e), are three (3) copies of CD-R compact discs containing the sequence listing labeled Copy 1, Copy 2 and computer-readable form (CRF) in accordance with 37 CFR § 1.824. The compact discs are formatted from an IBM-PC and are compatible with MS-Windows. The compact discs contain the following file: 2051004.txt, containing 428KB. This file was created on December 1, 2006.

The substitute Sequence Listing contained on the enclosed CDs complies with the requirements of 37 C.F.R. §1.52 and 37 C.F.R. §§1.821-1.825 and is identical to the paper sequence listing as originally filed. In accordance with 37 C.F.R. §1.825(a) and (b), I hereby state that the content of the computer-readable form (CRF) is identical to the content of the CD-R compact discs, and does not contain new matter.

Dated: December 4, 2006

Respectfully submitted,

By 
Sharon M. Sintich

Registration No.: 48,484

MARSHALL, GERSTEIN & BORUN LLP


233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357


(312) 474-6300

Agent for Applicant



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 4, 2006


(Sharon M. Sintich)

Docket No.: 30847/2051-004
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Helgadottir et al.

Confirmation No.: 6429

Application No.: 10/769,744

Art Unit: 1646

Filed: January 30, 2004

Examiner: Not Yet Assigned

For: **SUSCEPTIBILITY GENE FOR
MYOCARDIAL INFARCTION, STROKE,
AND PAOD; METHODS OF TREATMENT**

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO
ACID SEQUENCE DISCLOSURE**

MS Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This amendment is in response to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed October 3, 2006. The Notice required the submission of a replacement sequence listing statement in compliance with 37 C.F.R. § 1.821-1.825. This response is timely filed.

Prior to examination on the merits, please amend the above-identified patent application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Sequence Listing begin on page 3 of this paper.

Remarks begin on page 4 of this paper.

JFW



DEC 06 2006
PATENT AND TRADEMARK OFFICE
U.S. DEPARTMENT OF COMMERCE

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/769,744	01/30/2004	Anna Helgadottir	2345.2051-004

CONFIRMATION NO. 6429

04743
MARSHALL, GERSTEIN & BORUN LLP
233 S. WACKER DRIVE, SUITE 6300
SEARS TOWER
CHICAGO, IL 60606

FORMALITIES
LETTER

Date Mailed: 10/03/2006

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

To Download Patentin Software, visit <http://www.uspto.gov/web/patents/software.htm>
For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Replies should be mailed to: Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

*A copy of this notice **MUST** be returned with the reply.*

1800
Office of Initial Patent Examination (571) 272-4000, or 1-800-PTO-9199, or 1-800-972-6382
PART 2 - COPY TO BE RETURNED WITH RESPONSE